About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Anti-Inflammatory Therapeutics Market Size, Value & Trends | By 2033
Anti-Inflammatory Therapeutics Market

Anti-Inflammatory Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Biologics), By Indications (Arthritis, Psoriasis, Respiratory Diseases, Multiple Sclerosis, Anti-inflammatory Bowel Disease, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI3398DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Anti-Inflammatory Therapeutics Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Anti-inflammatory Biologics
        1. By Value
      3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        1. By Value
      4. Corticosteroids
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Arthritis
        1. By Value
      3. Anti-inflammatory Bowel Disease (IBD)
        1. By Value
      4. Respiratory Disease
        1. By Value
      5. Multiple Sclerosis
        1. By Value
      6. Psoriasis
        1. By Value
      7. Others
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. Online Providers
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Anti-inflammatory Biologics
        1. By Value
      3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        1. By Value
      4. Corticosteroids
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Arthritis
        1. By Value
      3. Anti-inflammatory Bowel Disease (IBD)
        1. By Value
      4. Respiratory Disease
        1. By Value
      5. Multiple Sclerosis
        1. By Value
      6. Psoriasis
        1. By Value
      7. Others
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. Online Providers
        1. By Value
    5. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Anti-inflammatory Biologics
          1. By Value
        3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
          1. By Value
        4. Corticosteroids
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Arthritis
          1. By Value
        3. Anti-inflammatory Bowel Disease (IBD)
          1. By Value
        4. Respiratory Disease
          1. By Value
        5. Multiple Sclerosis
          1. By Value
        6. Psoriasis
          1. By Value
        7. Others
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. Online Providers
          1. By Value
    6. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Anti-inflammatory Biologics
        1. By Value
      3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        1. By Value
      4. Corticosteroids
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Arthritis
        1. By Value
      3. Anti-inflammatory Bowel Disease (IBD)
        1. By Value
      4. Respiratory Disease
        1. By Value
      5. Multiple Sclerosis
        1. By Value
      6. Psoriasis
        1. By Value
      7. Others
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. Online Providers
        1. By Value
    5. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Anti-inflammatory Biologics
          1. By Value
        3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
          1. By Value
        4. Corticosteroids
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Arthritis
          1. By Value
        3. Anti-inflammatory Bowel Disease (IBD)
          1. By Value
        4. Respiratory Disease
          1. By Value
        5. Multiple Sclerosis
          1. By Value
        6. Psoriasis
          1. By Value
        7. Others
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. Online Providers
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Anti-inflammatory Biologics
        1. By Value
      3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        1. By Value
      4. Corticosteroids
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Arthritis
        1. By Value
      3. Anti-inflammatory Bowel Disease (IBD)
        1. By Value
      4. Respiratory Disease
        1. By Value
      5. Multiple Sclerosis
        1. By Value
      6. Psoriasis
        1. By Value
      7. Others
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. Online Providers
        1. By Value
    5. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Anti-inflammatory Biologics
          1. By Value
        3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
          1. By Value
        4. Corticosteroids
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Arthritis
          1. By Value
        3. Anti-inflammatory Bowel Disease (IBD)
          1. By Value
        4. Respiratory Disease
          1. By Value
        5. Multiple Sclerosis
          1. By Value
        6. Psoriasis
          1. By Value
        7. Others
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. Online Providers
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Anti-inflammatory Biologics
        1. By Value
      3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        1. By Value
      4. Corticosteroids
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Arthritis
        1. By Value
      3. Anti-inflammatory Bowel Disease (IBD)
        1. By Value
      4. Respiratory Disease
        1. By Value
      5. Multiple Sclerosis
        1. By Value
      6. Psoriasis
        1. By Value
      7. Others
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. Online Providers
        1. By Value
    5. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Anti-inflammatory Biologics
          1. By Value
        3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
          1. By Value
        4. Corticosteroids
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Arthritis
          1. By Value
        3. Anti-inflammatory Bowel Disease (IBD)
          1. By Value
        4. Respiratory Disease
          1. By Value
        5. Multiple Sclerosis
          1. By Value
        6. Psoriasis
          1. By Value
        7. Others
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. Online Providers
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Anti-inflammatory Biologics
        1. By Value
      3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        1. By Value
      4. Corticosteroids
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Arthritis
        1. By Value
      3. Anti-inflammatory Bowel Disease (IBD)
        1. By Value
      4. Respiratory Disease
        1. By Value
      5. Multiple Sclerosis
        1. By Value
      6. Psoriasis
        1. By Value
      7. Others
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacies
        1. By Value
      3. Retail Pharmacies
        1. By Value
      4. Online Providers
        1. By Value
    5. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Anti-inflammatory Biologics
          1. By Value
        3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
          1. By Value
        4. Corticosteroids
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Arthritis
          1. By Value
        3. Anti-inflammatory Bowel Disease (IBD)
          1. By Value
        4. Respiratory Disease
          1. By Value
        5. Multiple Sclerosis
          1. By Value
        6. Psoriasis
          1. By Value
        7. Others
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacies
          1. By Value
        3. Retail Pharmacies
          1. By Value
        4. Online Providers
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Anti-Inflammatory Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Eli Lilly and Company   
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. F. Hoffmann-La Roche AG   
    3. Pfizer Inc.   
    4. GSK   
    5. Johnson & Johnson Services, Inc.   
    6. Novartis AG   
    7. AstraZeneca PLC   
    8. Amgen Inc.   
    9. Merck & Co., Inc.   
    10. Ferring Pharmaceuticals   
    11. Bioventus LLC   
    12. Zimmer Biomet Holdings, Inc.   
    13. Flexion Therapeutics, Inc.   
    14. Bayer AG   
    15. Dr. Reddy’s Laboratories Ltd
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global anti-VEGF therapeutics market size was valued at USD 12.3 billion in 2022. It is estimated to reach USD 13.7 billion by 2031, growing at a CAGR of 0.6% during the forecast period (2023–2031). The human body naturally produces VEGF,
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.